SNDX — Syndax Pharmaceuticals Balance Sheet
0.000.00%
- $1.44bn
- $1.33bn
- $23.68m
Annual balance sheet for Syndax Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 298 | 447 | 484 | 578 | 583 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.175 | 0.429 | 4.06 | 1.23 | 13.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 299 | 448 | 490 | 581 | 603 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.482 | 1.26 | 1.06 | 1.5 | 2.02 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 301 | 450 | 497 | 613 | 725 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.9 | 20.7 | 29.1 | 58.1 | 104 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 48.4 | 41.3 | 29.8 | 58.7 | 437 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 252 | 408 | 467 | 554 | 288 |
| Total Liabilities & Shareholders' Equity | 301 | 450 | 497 | 613 | 725 |
| Total Common Shares Outstanding |